Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Crinetics Pharmaceuticals Inc.
Exelixis
Cedars-Sinai Medical Center
Boston Scientific Corporation
Cook Group Incorporated
Hutchmed